GOVX - GeoVax Labs, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4000
-0.0750 (-15.79%)
As of 3:01PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4750
Open0.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3600 - 0.4500
52 Week Range0.3600 - 20.0000
Volume56,902
Avg. Volume10,454
Market Cap244,035
Beta (3Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-6.8030
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.56
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    GeoVax Announces Upcoming Presentation of Lassa Fever Vaccine Data

    ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior Scientist, Mugdha Vasireddi, PhD, will deliver an oral presentation entitled, A Single Dose of MVA-Based Lassa Virus Vaccine Provides Complete Protection in a Mouse Lethal Challenge Model. The presentation will be given during the Annual Meeting of the American Society for Virology, being held July 20-24 in Minneapolis, Minnesota. In her talk, Dr. Vasireddi will discuss the preclinical efficacy studies of GEO-LM01, a novel vaccine candidate for Lassa fever constructed on an MVA vector expressing two immunogens derived from the Lassa virus.

  • Zacks Small Cap Researchlast month

    GOVX: Convertible Preferred Shares Barrier to Advancement

    Since the year began, GeoVax announced collaborations with Enesi Pharma, expanded a collaboration with Leidos, was published in the Atlas of Science and effected a 1:500 reverse stock split. Looking forward to the rest of 2019, we expect a capital raise which will enable the advancement of the HIV and Zika programs, the start of the Phase IIb HVTN efficacy trial and the launch of a Phase I collaboration with AGT for an HIV cure. Grant and collaboration revenues for 1Q:19 were $364,000, representing a 65% increase over 1Q:18 levels.

  • GlobeNewswire2 months ago

    GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress

    ATLANTA, May 14, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVXD), a biotechnology company developing human vaccines, today announced its financial results for the three months ended.

  • GlobeNewswire3 months ago

    Update: GeoVax Announces Reverse Stock Split

    1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA , May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX) today.

  • GlobeNewswire3 months ago

    GeoVax Announces Reverse Stock Split

    1:500 Reverse Split Effective May 2, 2019;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, May 03, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX).

  • GlobeNewswire3 months ago

    GeoVax Recognizes World Malaria Day 2019

    ATLANTA, GA, April 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) today is observing World Malaria Day, an annual international event held on April 25th each year to recognize global efforts to control and ultimately eradicate malaria.  GeoVax is commemorating World Malaria Day 2019 by highlighting the efforts of its scientists and collaborators toward the development of a much-needed effective vaccine against this disease. Malaria is a mosquito-borne disease caused by Plasmodium parasites. Nearly half of the world’s population (over 3 billion people) are at risk of malaria infection.

  • Zacks Small Cap Research3 months ago

    GOVX: 2018 Financial & Operational Review

    GeoVax Labs, Inc. (GOVX) held its special meeting of stockholders and shareholder vote on April 15, 2019. While many shareholders were concerned that the reverse stock split would lead to poor prospects for future share price performance, the authority was necessary. GeoVax was running out of authorized shares and would not be able to raise funds using equity as there would be insufficient shares to offer for sale.

  • GlobeNewswire4 months ago

    GeoVax Reports 2018 Year-End Financial Results

    ATLANTA, March 27, 2019 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the year ended December.

  • Zacks Small Cap Research4 months ago

    GOVX: GeoVax Published in Atlas of Science

    GeoVax (GOVX) recently had its Ebola Vaccine Study published in the Atlas of Science. The article, entitled Single Dose Protection Against Ebola Virus Challenge, highlights the importance of an Ebola vaccine that can be stored at room temperature and minimizes severe adverse events. GeoVax’s GEO-EM01 has demonstrated these characteristics in preclinical studies.

  • GlobeNewswire4 months ago

    GeoVax Ebola Vaccine Study Published in the Atlas of Science

    GeoVax Ebola Vaccine Provides Potential for 100% Protection from Single-Dose ATLANTA, GA, March 19, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire4 months ago

    GeoVax Selected as Finalist for Vaccine Industry Excellence Awards

    Selection in Two Award Categories follows GeoVax receiving the 2018 Best Biotech Award ATLANTA, GA, March 12, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire4 months ago

    GeoVax Provides Product Development and Corporate Update

    ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector platform technology, today provided an update on its progress and development programs. David Dodd, GeoVax President and CEO, commented, “We continue to advance GeoVax’s development programs on multiple fronts with an expanding list of world-class government, academic and corporate collaborators, as further described in this update. Going forward, we will continue to evaluate options to secure the capital needed to proceed with our business plan, especially to advance further programs into human clinical testing.

  • GlobeNewswire5 months ago

    GeoVax and Leidos Expand Collaboration to Malaria Vaccines

    Supported by Contract from U.S. Agency for International Development (USAID) ATLANTA, GA, March 04, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire5 months ago

    GeoVax Issues Open Letter to HHS Secretary Alex Azar

    Comments on HHS Initiative “Ending the HIV Epidemic: A Plan for America” ATLANTA, GA, Feb. 14, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology.

  • GeoVax Recognizes National Black HIV/AIDS Awareness Day
    GlobeNewswire5 months ago

    GeoVax Recognizes National Black HIV/AIDS Awareness Day

    Today, individuals and organizations across the country will observe National Black HIV/AIDS Awareness Day. GeoVax is commemorating the day by celebrating the progress toward the development of a vaccine against HIV, recognizing the work yet to be done, and bringing attention to the continued HIV epidemic in the United States and the disproportionate impact of the disease on African-Americans.

  • GlobeNewswire5 months ago

    GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message

    During Tuesday night’s State of the Union address, President Donald Trump asked Congress to support his goal of eliminating the HIV epidemic in America within 10 years. GeoVax’s President and CEO, David Dodd, responded today. “We applaud President Trump for using such a high-profile setting to bring attention to the continued HIV epidemic in the United States,” Mr. Dodd commented.

  • GlobeNewswire6 months ago

    GeoVax Zika Vaccine Study Published in the Atlas of Science

    GeoVax Zika Vaccine Provides Potential for 100% Protection & Reduced Side-Effect Risks ATLANTA, GA, Jan. 24, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire6 months ago

    GeoVax to Present at the 2019 ASM Biothreats Conference

    ATLANTA, GA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, announced that Senior Scientist, Mary Hauser, PhD, will deliver a presentation, entitled “Development of a Safe and Effective Single-Dose Vaccine for Emerging Infectious Diseases, Preclinical Data for Zika, Ebola and Lassa Fever as Examples,” during the 2019 American Society for Microbiology (ASM) Biothreats Conference, being held January 29-31, 2019 in Arlington, Virginia. Dr. Hauser will discuss GeoVax’s “Plug and Play” vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated. The MVA-VLP platform has several advantages including the ability to use single inoculations to achieve full protection.

  • Zacks Small Cap Research7 months ago

    GOVX: A Preventive and Therapeutic Portfolio

    We visited with GeoVax (GOVX) management at their facilities in Smyrna, Georgia to review their key programs and identify the expected path forward for the company. Over the last few years, GeoVax has expanded from a single program developing an HIV vaccine to a platform company that is using its modified vaccinia Ankara virus-like particles (MVA-VLP) technology to address a broad portfolio of hemorrhagic fevers, hepatitis viruses, malaria and cancer. GeoVax’s most advanced program is a vaccine for human immunodeficiency virus (HIV), Clade B, which has completed a Phase IIa trial.

  • GeoVax and Enesi Pharma to Collaborate on Development of Multiple Vaccines Administered by ImplaVax®, a Novel Needle-Free Vaccine Delivery Platform
    GlobeNewswire7 months ago

    GeoVax and Enesi Pharma to Collaborate on Development of Multiple Vaccines Administered by ImplaVax®, a Novel Needle-Free Vaccine Delivery Platform

    Potential for Addressing Multiple Infectious Disease Targets ATLANTA, GA and OXFORD, UK, Jan. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a.

  • GlobeNewswire7 months ago

    GeoVax Comments on 2018 Ebola Outbreak

    David Dodd, GeoVax President and CEO, stated, “The ongoing Ebola outbreak in DRC is now among the deadliest in history, second only to the 2014-16 outbreak in several African nations that infected 28,652 people and killed 11,325. As of December 8, 2018, there have been 446 confirmed cases of Ebola in the Congo with 235 deaths, which disproportionally affected women and young children. There is currently no licensed vaccine to protect people from the Ebola virus. An experimental vaccine with a limited supply is being used in a “ring vaccination” approach.

  • GeoVax Observes 2018 World AIDS Day
    GlobeNewswire7 months ago

    GeoVax Observes 2018 World AIDS Day

    World AIDS Day is a global initiative to raise awareness, fight prejudice, and improve education about HIV and AIDS. “The U.S. federal theme for the 2018 World AIDS Day observance is Saving Lives through Leadership and Partnerships,” commented David Dodd, President & CEO of GeoVax. “GeoVax is committed to an AIDS-free generation through vaccine development, and today we would like to recognize and thank our many collaborators and partners, both current and past, who have helped advance our vaccine candidates.

  • GlobeNewswire8 months ago

    GeoVax Provides Update on HIV Clinical Trials Program

    ATLANTA, GA, Nov. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines, today provided an update of the clinical development plan for its preventive vaccine (GOVX-B11) for clade B HIV. The HIV Vaccine Trials Network (HVTN) is moving forward with plans for a phase 1 trial, designated HVTN 132, which will be a multi-center, randomized, double-blind trial, enrolling up to 70 healthy adults. The primary objectives of the trial will be to assess the safety, tolerability and immunogenicity (elicited antibody responses) of a prime-boost regimen of GOVX-B11, in combination with protein boosts.

  • Zacks Small Cap Research8 months ago

    GOVX: Lassa Grant from DoD Provides Capital

    By John Vandermosten, CFA OTC:GOVX READ THE FULL GOVX RESEARCH REPORT GeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update ...

  • GlobeNewswire8 months ago

    GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program

    The project will include the design, construction, and characterization of multiple immunotherapeutic vaccine candidates using GeoVax’s MVA-VLP vaccine platform combined with certain novel peptide PD-1 checkpoint inhibitors developed by Leidos. The vaccine design, construction, and characterization will be performed at GeoVax with further analysis conducted by Leidos. GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated.